Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/
Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)
The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercialized by MSD, which is known as Merck in the United States and Canada.
“Breast cancer remains the most common form of cancer affecting women. We hope ONTRUZANT will play an important role expanding patient access to trastuzumab across the region,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry's strongest biosimilar pipelines, so that more cancer patients and healthcare systems across Europe will benefit from biosimilars.”
ONTRUZANT ® is the fourth biosimilar developed by Samsung Bioepis to receive EC marketing authorization. Samsung Bioepis has also received marketing authorizations for Benepali ® (etanercept), Flixabi ® (infliximab) and Imraldi ® (adalimumab).
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six first-wave candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.
i Herceptin ® is a registered trademark of Genentech Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171119005066/en/
Contact information
MEDIA CONTACT:
Samsung Bioepis Co., Ltd.
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EBP Shareholders Enter into Exclusive Negotiations with Cegid to Create a European Leader in the Highly Strategic and Growing Market for Micro and SMB Enterprise Software24.4.2024 16:36:00 EEST | Press release
Cegid, a European leader in cloud business management solutions for finance (treasury, tax, ERP), human resources (payroll, talent management), CPAs, retail and entrepreneurial sectors, strengthens its position in the fast-growing sector of invoicing and accounting software solutions for the Micro and SMB segments through the potential acquisition of EBP, one of the leading enterprise software providers in this market segment. Following Cegid’s investments in Iberia and Belgium, this major step will allow the new Cegid Group to become the leader in this high-growth market segment ahead of the implementation of mandatory e-invoicing. EBP, established as one of the leading solutions providers in France known for its long-standing expertise in working with Micro and SMB businesses, its user-centered approach and its distinctive know-how, has been serving its customer base of 275,000 companies using its solutions in France for close to 40 years. The acquisition of EBP represents a major st
Exergen Sues Baxter International to Defend Its Right to Publish Data Regarding the Accuracy of Oral Thermometers24.4.2024 16:00:00 EEST | Press release
Last week Exergen Corporation filed a lawsuit against Baxter International Inc. in the United States District Court for the District of Massachusetts. As detailed in its complaint, Exergen’s lawsuit is a response to an effort by Baxter to censor true statements that Exergen has made in a scientific journal about a matter of public concern, among other issues. Through its lawsuit, Exergen seeks a legal declaration that its statements are not only true, but that they constitute First Amendment protected speech. Exergen looks forward to having this matter resolved in a court of law. Click here to read the formal complaint. About Exergen Corporation Exergen invented, manufactures, and markets two series of the TemporalScanner thermometer: a professional version for hospitals and clinics, and a consumer version sold in major retailers nationwide. More than three billion temperatures are taken each year with TemporalScanners. Used in thousands of hospitals and clinics across the country as w
‘World of Coffee & World Barista Championship Busan 2024’ to Launch on May 1st24.4.2024 16:00:00 EEST | Press release
Global coffee figures and baristas will gather at BEXCO, Busan in May. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424527060/en/ World of Coffee & World Barista Championship Busan is held from May 1st to 4th at BEXCO, Busan. (Graphic: EXPORUM) Specialty coffee industry professionals from around the world will gather at BEXCO, Busan, from May 1-4, 2024, for the inaugural World of Coffee in Asia. This event will also feature the 2024 World Barista Championship, bringing together top baristas from across the globe. The Specialty Coffee Association (SCA) is working with host Busan Metropolitan City and organizer EXPORUM, with support of the 2024 Portrait Country, Indonesia, to debut World of Coffee in Busan, marking a significant milestone for the Asian coffee community. Over 20,000 global attendees, including 12,000 industry professionals from 70+ countries, are expected to visit BEXCO, anticipating contributions not only
Open Source Database Leader Percona Appoints Liz Warner to Chief Technology Officer24.4.2024 16:00:00 EEST | Press release
Percona, a leader in enterprise-grade, open source database software, support, and services, today announced the appointment of Liz Warner as its new Chief Technology Officer, to help meet the growing demand to make data simpler, faster, and easier to manage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424498483/en/ Liz Warner, Chief Technology Officer, Percona (Photo: Business Wire) An industry veteran, Warner comes to Percona with decades of technical and senior leadership experience; including a proven track record of driving successful organizational transformations. As CTO, she will play an instrumental role in the development and implementation of Percona’s ever-expanding collection of database solutions, including the much-anticipated Percona Everest, an open source cloud-native database platform. “We’ve reached a pivotal moment in open source, and Percona is doubling down on its commitment to staying open throu
The Antera Brand Back at the Summit of Light Alloy-wheel Producers24.4.2024 15:23:00 EEST | Press release
The Antera brand makes its comeback on the world stage during the 2024 Milan Design Week with a new collection of light alloy wheels. A premium made-in-Italy brand, Antera combines timeless design, cutting-edge technology, and the determination to overcome any obstacle. Its ambassador is the football champion Roberto Baggio, who, thanks to his successful career and winning mindset, is the perfect embodiment of the Italian’s brand spirit of 'No Compromise'. The new Antera advertising campaign’s slogan, "Where instinct meets genius, the myth becomes legend", attests to the dedication, courage, and vision of a brand which is able to project itself into the future. Antera was founded in Milan in 1991 and has produced some of the most iconic models in the field, including the Type 109, a three-spoke wheel that was named as “Alloy Wheel Design of the Year 1994”. G.M.P. Group, a company specialized in the global design and production of alloy wheels, is responsible for bringing it back to its
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom